Jazz Pharmaceuticals (JAZZ) PT Lowered to $193 at BMO Capital
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $253.07 +1.90%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
BMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $193.00 (from $205.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Biotech funding rises 75% this year as M&A activity continues
- Nebius Group (NBIS) PT Raised to $250 at DA Davidson
- Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
